阅读说明：本技术 天然三萜-环烯醚萜苷二聚体杂合物在制备乙酰辅酶a羧化酶1抑制剂中的用途 (Use of natural triterpene-iridoid glycoside dimer heterozygote in preparation of acetyl-CoA carboxylase1 inhibitor ) 是由 胡金锋 万江 熊娟 金则新 姜春筱 于 2021-06-25 设计创作，主要内容包括：本申请公开一种结构式如式(1)所示的三萜-环烯醚萜苷二聚体杂合物在制备乙酰辅酶A羧化酶1抑制剂中的用途：本申请在ACC1抑制生物学实验中发现该化合物具有显著的ACC1抑制作用,可用于制备由ACC1所介导疾病的药物或是作为该类药物的先导化合物。对肥胖症、2型糖尿病、非酒精性脂肪肝、癌症及其它ACC1所介导的疾病具有治疗作用,从而在制药领域有巨大的潜在用途。(The application discloses an application of a triterpene-iridoid glycoside dimer heterocomplex with a structural formula shown as a formula (1) in preparing an acetyl-CoA carboxylase1 inhibitor:)

1. Use of a triterpene-iridoid glycoside dimer hybrid having the structural formula shown in formula (1) in the preparation of an acetyl-CoA carboxylase1 inhibitor:

2. an acetyl-coa carboxylase1 inhibitor comprising a therapeutically effective amount of a triterpene-iridoid glycoside dimer hybrid represented by the formula (1):

3. the acetyl-coa carboxylase1 inhibitor according to claim 2, wherein the triterpene-iridoid glycoside dimer hybrid is formulated with an excipient into a tablet, a pill, a capsule or a granule.

4. Use of a triterpene-iridoid glycoside dimer hybrid having a structural formula as shown in formula (1) in the preparation of a medicament for preventing, delaying or treating diseases mediated by acetyl-CoA carboxylase 1:

5. the use according to claim 4, wherein the disease mediated by acetyl-CoA carboxylase1 comprises obesity, type 2 diabetes, non-alcoholic fatty liver disease or cancer.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of a triterpene-iridoid glycoside dimer hybrid according to formula (1):

Technical Field

The application belongs to the technical field of medicines, and particularly relates to application of a natural triterpene-iridoid glycoside dimer heterocomplex in preparation of medicines or medicine lead compounds for preventing or treating diseases (such as obesity, type 2 diabetes, non-alcoholic fatty liver and the like) related to glycolipid metabolic disorder mediated by acetyl-CoA carboxylase1 (ACC 1).

Background

acetyl-CoA carboxylase 1(acetyl-CoA carboxylase1, ACC1) has both functions of biotin carboxylase and carboxytransferase, and plays a role of a rate-limiting enzyme in the synthesis of long-chain fatty acids, and can catalyze the carboxylation of acetyl-CoA to malonyl-CoA. The human ACC1 gene is located in chromosome 17q12, the molecular weight of the corresponding protein is 165kDa, and the protein is highly expressed mainly in tissues such as liver, adipose tissue and mammary gland with active lipogenesis (Munday et al biochem. Soc. Trans.2002,30,1059-1064), and promotes the synthesis of fatty acid in cytoplasm. Malonyl-coa, which is catalytically produced, is the C2 donor which provides carbon chain elongation from de novo synthesis of long chain fatty acids. In addition, malonyl-coa can also replace different fatty acetyl-coa elongases. ACC1 plays a key role in fatty acid biosynthesis and metabolism, and its expression changes are closely related to human obesity, type 2 diabetes, non-alcoholic fatty liver disease, cancer, and the like.

Obesity is a chronic metabolic disease caused by multiple factors, is increased in volume and number of fat cells in a body, is abnormally high in percentage of body fat, and excessively deposits fat locally, and is a major risk factor for various chronic diseases including type 2 diabetes, cardiovascular and cerebrovascular diseases, and various malignant tumors. Now having become a global public problem, studies have found that high body mass index over the last 25 years is associated with deaths of 400 million people worldwide, accounting for 7.1% of all-cause deaths (Afshin et al, N.Engl. J.Med.,2017,377,13-27), with the number of obesity people in our country being the first global (NCD-RisC, Lancet,2016,387, 1377-1396). The search for drugs for preventing or treating obesity has become a priority of global public health.

ACC1 is a key enzyme in the fatty acid synthesis process, carboxylating acetyl-coa under ATP-powered conditions, catalyzing the production of malonyl-coa, and regulating lipid metabolism in the body. Therefore, the search for a potent ACC1 inhibitor has very important application prospects for treating or preventing the occurrence of obesity. In addition, lipid metabolism abnormalities also increase the risk factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Type II Diabetes Mellitus (T2 DM), and therefore ACC1 may also be a potential target for Nonalcoholic Fatty Liver and Type II Diabetes Mellitus (Alkhouri et al, Expert Opin. Inv. drug,2020,29, 135-.

Studies have shown that ACC1 is also closely associated with the development of cancer. The increase in lipid synthesis, which provides the necessary lipids for cell growth and division, is one of the important hallmarks of Cancer, and also an early event in tumorigenesis (Migita et al, Cancer Res.2008,68, 8547-8554). acetyl-CoA is an important component of de novo synthesis of fatty acid, ACC1 can catalyze the conversion of acetyl-CoA into lipid, and inhibition of the expression of the gene can significantly inhibit the proliferation of tumor cells and induce the apoptosis of the tumor cells. Therefore, ACC1 has been extensively studied as a potential target for anticancer in recent years, and finding a potent inhibitor thereof is expected to become a new anticancer drug (Singh et al, Oncogene,2021,40, 592-doped 602; Huang et al, Eur.J.Med.Chem.,2021,212,113036; Dyck et al, Cancer Lett.,2018,417, 11-20).

ACC1 has become a hot spot of recent research on innovative drugs for diseases with dysglycolipid metabolism as a new medicinal target. With the widespread use of high-throughput screening technologies, a wide variety of ACC1 small molecule inhibitors have been successively discovered (Mizojiri et al, J.Med.chem.,2018,61, 1098-. However, no ACC1 inhibitor has been successfully marketed, and the competition in the medical field is very strong. GS-0976 is a potent allosteric inhibitor of ACC that interacts within the ACC phosphopeptide receptor and dimerization site to prevent dimerization and to inhibit ACC isozyme activity, currently in phase II in the clinic, for the treatment of obesity and a variety of metabolic disorders (Loomba et al, Gastroenterology,2018,155, 1463-. In addition to GS-0976, other ACC1 inhibitors have been limited in development due to their low cell penetration, low affinity for ACC1, and poor specificity. Therefore, the finding of the small-molecule ACC1 inhibitor which is efficient and highly selective and has good pharmacokinetic properties is of great significance, and the small-molecule ACC1 inhibitor has a wide application prospect in treatment of diseases such as metabolic disorders and cancers.

Disclosure of Invention

The application provides an application of a natural triterpene-iridoid glycoside dimer heterozygote in preparation of an acetyl-CoA carboxylase1 inhibitor, and the ACC1 dimer heterozygote is found to have a remarkable ACC1 inhibition effect in ACC1 inhibition biological experiments.

Use of a triterpene-iridoid glycoside dimer hybrid having the structural formula shown in formula (1) in the preparation of an acetyl-CoA carboxylase1 inhibitor:

the compounds are triterpene-iridoid glycoside dimer heterocomplexes separated from the root of Daphne avellana, have obvious ACC1 inhibition effect in ACC1 inhibition biological experiments, and can be used for preparing medicines for treating ACC 1-mediated diseases or lead compounds of the medicines. Therefore, the medicine composition has a treatment effect on obesity, type 2 diabetes, non-alcoholic fatty liver disease, cancer and other ACC1 mediated diseases, and has huge potential application in the field of pharmacy.

The present application also provides an acetyl-coa carboxylase1 inhibitor comprising a therapeutically effective amount of a triterpene-iridoid glycoside dimer hybrid represented by the formula (1):

the compounds described herein can be used alone or in combination, or can be combined with pharmaceutically acceptable carriers or excipients and formulated into oral or non-oral dosage forms according to conventional methods.

Optionally, the triterpene-iridoid glycoside dimer heterocomplex is formulated with excipients into tablets, pills, capsules or granules.

The application also provides an application of the natural triterpene-iridoid glycoside dimer heterocomplex with the structural formula shown in the formula (1) in preparing medicines for preventing, delaying or treating obesity, type 2 diabetes, non-alcoholic fatty liver or cancer:

the present application also provides a pharmaceutical composition comprising a pharmaceutically effective amount of a triterpene-iridoid glycoside dimer hybrid represented by the formula (1):

the compounds described herein can be used alone or in combination, or can be combined with pharmaceutically acceptable carriers or excipients and formulated into oral or non-oral dosage forms according to conventional methods.

The compounds described herein can be isolated and purified from plants; can also be obtained by chemical synthesis methods well known to those skilled in the art.

In an alternative preparation method, the separation and extraction from the Dahualiu wood comprises the following steps:

(1) drying and crushing six large flowers; extracting with 75% ethanol solution at room temperature for several times; filtering, and mixing extractive solutions; concentrating under reduced pressure to obtain total extract;

(2) dispersing the total extract in water, and sequentially extracting with petroleum ether, ethyl acetate and n-butanol of equal volume; concentrating the extractive solution under reduced pressure to obtain petroleum ether component, ethyl acetate component and n-butanol component;

(3) subjecting the ethyl acetate component to macroporous resin column chromatography, performing gradient elution with ethanol-water volume ratio of 30:70 → 50:50 → 70:30 → 85:15 → 100:0, and collecting eluate components of different volume ratios;

(4) subjecting the eluate fraction with a volume ratio of ethanol to water of 100:0 to Sephadex LH-20 column chromatography and then to semi-preparative HPLC purification at 14.5min and 15.9min, respectively, to obtain abelifoloside A and abelifoloside B in the triterpene-iridoid glycoside dimer heterozygote according to claim 1.

The application discovers that the compound abelifloroside B has obvious inhibiting effect on ACC1 through screening, and IC₅₀The value was 7.9. mu.M. The results show that the compound has a treatment effect on obesity, type 2 diabetes, non-alcoholic fatty liver, cancer and other ACC1 mediated diseases, so that the compound has great potential application in the field of pharmacy.

Detailed Description

The technical solutions of the present application will be described clearly and completely with reference to the following embodiments, and it should be understood that the described embodiments are only a part of the embodiments of the present application, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the description of the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

The natural product has the characteristics of structural complexity and structural diversity, and is an important source for new drug discovery. The natural product and the derivative thereof have unique chemical structures, so that the natural product and the derivative thereof have the advantages of low toxic and side effects, high Drug effect, high selectivity to specific targets, potential unique action mechanism and the like (Atanaasov et al, nat. Rev. Drug Discov.,2021,20, 200-216; Newman et al, J.nat. prod.2020,83: 770-803; Tiago et al, nat. chem.2016,8: 531-541). Therefore, the search for and development of novel and efficient ACC1 inhibitors from natural active ingredients has important research value.

The Dahua six-wood (Abelia x grandiflora) is an evergreen shrub of six-wood (Abelia) of Caprifoliaceae (Caprifoliaceae), and is mainly distributed in east, southwest and north China. The plant is a hybrid of glutinous rice strips (A. chinensis) and peduncles (A. uniflora), the height of the plant can reach 1.8 meters, young branches are smooth and reddish brown, leaves are inverted egg-shaped, dark green and glossy, flowers are white and bell-shaped, and are funnel-shaped, and the flowering period is continuously full-bloom from 5 months to 11 months. At present, the chemical components and related biological activities of the buds are not reported. The application separates abelifloroside B from 75% ethanol extract of buds of the dahlia hexapetala for the first time:

multiple pharmacological test researches show that the compounds have obvious ACC1 inhibitory activity, can be used for preparing medicines for preventing, delaying or treating obesity, type 2 diabetes, non-alcoholic fatty liver disease, cancer and other ACC1 mediated diseases, and therefore have huge potential application in the field of pharmacy.

The following is a description of specific examples:

six major flowers are collected from the zanthoxylum bungeanum area in Taizhou city of Zhejiang province, dried in the shade and crushed into powder; specific optical rotation test was performed by Rudolf Autopol IV polarimeter at 21 ℃; the ultraviolet and infrared spectrum data are respectively obtained by testing a Hitachi U-2900E type ultraviolet spectrometer and a Thermo Scientific Nicolet Is5 FT-IR type infrared spectrometer; low resolution mass spectrometry (ESI-MS) and high resolution mass spectrometry (HR-ESI-MS) were obtained by an Agilent 1100LC/MSD type mass spectrometer and an AB Sciex Triple TOF 5600 type mass spectrometer, respectively, using an ESI ion source to obtain both positive and negative ion modes; NMR was obtained from a Bruker AvanceII400 NMR spectrometer and a Bruker Avance II 600 NMR spectrometer, chemical shifts being referenced to the non-deuterated residual solvent peak and expressed in delta (ppm); thin layer chromatography plates (TLC) used for the analysis were purchased from Nicotiana, and developed using UV (. lamda.: 254nm, 365nm) and sulfuric acid-vanillin solution; column chromatography mainly used MCI microporous resin CHP 20P (Mitsubishi Chemical Industries,75-150 μm), gel Sephadex LH-20(GE Healthcare BioSciences AB); analytical and semi-preparative liquid phase Waters e2695 equipped with Waters 2998Photodiode Array Detector (PDA) and Waters 2424 Evaporation Light-Scattering Detector (ELSD) detectors and Waters Sunfire columns (5 μm, 250X 10 mm); the analytically pure solvents used in the experiments, methanol, ethanol and the like, were purchased from Shanghai Tatan chemical Co., Ltd, and the chromatographic grade methanol and acetonitrile were purchased from Beijing carbofuran.

Example 1: preparation of compound abelifloroside B

Drying bud of Larix Gmelini (A. times. grandiflora), pulverizing, and extracting with 75% ethanol solution at room temperature for 5 times (2L each time) for 24 hr. Filtering and combining the extracting solutions, and concentrating under reduced pressure to obtain 67g of total extract (semi-dry). After the total extract is dispersed by 1L of water, the total extract is extracted by petroleum ether, ethyl acetate and n-butanol with equal volumes for three times. The extract was concentrated under reduced pressure to give a petroleum ether fraction (17.2g), an ethyl acetate fraction (16.3g) and an n-butanol fraction (20.6 g).

The ethyl acetate fraction (16.3g) was subjected to macroporous resin column chromatography and gradient elution with ethanol-water (30:70 → 50:50 → 70:30 → 85:15 → 100: 0; v/v), and the resulting lower column liquids were collected, subjected to color development detection by TLC thin layer chromatography, combined with the lower column liquids having the same spots, and finally subjected to color development by TLC into 5 fractions Fr.1 to Fr.5. The fraction Fr.5 (ethanol-water v/v 100:0 eluate fraction) was subjected to Sephadex LH-20(MeOH) column chromatography and then to semi-preparative HPLC (MeCN-H)₂O,88: 12; v/v,3mL/min) to give compound abelifloroside B (1.2mg, t)_R＝15.9min)。

The physicochemical data for the compounds are as follows:

abelifloroside B as a white amorphous powder; [ alpha ] to]_D ²¹-31.7(c 0.1,MeOH)；UV(MeCN) λ_max(logε)233(3.47)nm；ECD(c 3.21×10^-3M,MeOH)λ_max(Δε):223(-16.6),247 (3.9)；IR(KBr)v_max 3423,3312,2970,2918,2827,1718,1644,1509,1443,1379, 1268,1194,1142,1077,803,771,674cm^-1；¹H and¹³c NMR data are shown in Table 1; ESIMS M/z 1039[ M + H ]]⁺；HRESIMS m/z 1039.5644[M+H]⁺(calcd for C₅₇H₈₂O₁₇,1039.5625, Δ＝1.9ppm).

TABLE 1 preparation of abelifloroside B¹H and¹³C NMR(in CD₃OD) data^a.

^aAssignmentswere made by a combination of 1D and 2D NMR experiments.

Example 2: ACC1 inhibition activity assay

The experimental method comprises the following steps: ACC1 is located in the liver and adipocytes and is a key enzyme in fatty acid synthesis, requiring biotin as a coenzyme and catalyzing the production of malonyl-CoA upon carboxylation of acetyl-CoA depending on the energy supplied by ATP, thereby regulating lipid metabolism. This reaction is also accompanied by the consumption of ATP, and therefore, the ADP-Glo kinase assay reagent can be used to detect changes in ATP, which indirectly reacts the inhibitory effect of the compound on the ACC1 enzyme.

Specifically, the monomeric compound isolated in example 1 was selected at the initial screening, and the percent inhibition of the enzymatic activity of ACC1 was examined at a concentration of 20. mu.g/mL, and the test results showed that the compound abelifloroside B inhibited 85.3%.

Further determination of IC₅₀The value: immediately before use, the samples were dissolved in DMSO to make appropriate concentrations, diluted 3-fold, diluted 7-fold, and triplicated wells, and 1. mu.L of the sample solution was added to a standard assay (40mM Tris, pH 8.0, 10mM MgCl2,5mM DTT, ATP, CoA, sodium citrate, and ACC1) and incubated at room temperature for 30 min. Then, 2.5. mu.L of ADP-Glo reagent was added to the system, and the reaction was allowed to proceed at room temperature for 1 hour, to consume the remaining ATP and terminate the reaction. And adding a kinase detection reagent for incubation for 30min, reading a fluorescence signal by EnVision, and taking the slope of the first-order reaction of a kinetic curve as an activity index of the enzyme. Plotting the relative activity against the concentration of the compoundFormula v/v₀＝100/(1+b*[I]/IC₅₀) Fitting to obtain IC₅₀Values, experiments were repeated three times and results were averaged over three times. ND-630(CAS:1434635-54-7) as a positive control (IC)₅₀：1.6±0.2nM)。

TABLE 2 ACC1 inhibitory Activity data for abelifloroside A and abelifloroside B in the buds of Rhus succedanea

Triterpene-iridoid glycoside dimer heterozygotes inhibit IC of ACC1₅₀The values are shown in table 2, and the test results show that the compounds show significant inhibitory activity to ACC1, which indicates that the compounds of the application can be used for preparing medicines for treating obesity, type 2 diabetes, non-alcoholic fatty liver disease, cancer and other ACC1 mediated diseases or lead compounds of the medicines.

The above-mentioned embodiments only express several embodiments of the present application, and the description thereof is more specific and detailed, but not construed as limiting the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the concept of the present application, which falls within the scope of protection of the present application. Therefore, the protection scope of the present patent shall be subject to the appended claims.